Rewiring the Chronic Pain Experience: Single-Session Model of Pain Reprocessing Therapy (PRT) at The Ottawa Hospital

October 30, 2026 updated by: Ottawa Hospital Research Institute

Rewiring the Chronic Pain Experience: Feasibility and Pilot Testing of a Single-Session, 4-Hour Delivery Model of Pain Reprocessing Therapy (PRT) at The Ottawa Hospital (TOH)

The goal of this study is to find out if a one-time session of Pain Reprocessing Therapy (PRT) intervention improves participant's mood and pain. Participants in this 4 hours session will be 40 patients who've been referred to the The Ottawa Hospital Pain Clinic (TOHPC) for chronic pain.

The main questions of this study are:

  • Can we recruit 40 participants within 6 months?
  • Do at least 32 participants complete the session and answer follow up questions?
  • Does 1 session of PRT have a positive impact on participants' mood and pain?

Participants in this study will:

  • Attend 1 session of PRT.
  • Answer questions that relate to their experience of pain and their mood. They will answer these questions immediately before/after the session, 1 week after the session, and 1 month after the session.
  • After the session, some participants will participate in an interview to talk about their experience.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Susan Ward, MSW
  • Phone Number: 72123 613-737-8899
  • Email: SWard@toh.ca

Study Contact Backup

Study Locations

    • Ontario
      • Ottawa, Ontario, Canada, K1H8L6
        • Recruiting
        • The Ottawa Hospital
        • Principal Investigator:
          • Susan Ward, MSW

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Minimum age of 18 years or older at time of consent.

  • Chronic pain persisting for a minimum of 3 months, consistent with the International Association for the Study of Pain (IASP) definition of chronic pain.

  • Self-reported 1-week average pain intensity score between 4/10 and 9/10 on the Brief Pain Inventory (BPI)12 at screening.

    o Note: Individuals scoring less than 4/10 or more than 9/10 will be directed to other pain clinic workshops and available resources (e.g., Power Over Pain)

  • Referred to TOHPC and triaged by a registered nurse, nurse practitioner, or physician to the "diffuse pain" pathway;

  • Completed the initial pain clinic patient education and resource session (PERS) for patients triaged to the "diffuse pain" pathway;

  • Currently waiting for a 1st consultation with the Nurse Practitioner assigned to the "diffuse pain" pathway.

  • Able to read, write, and communicate in English at a level sufficient to engage with research team, the psychoeducational content, and to complete self-report measures.

  • Able to attend a single, in-person 4-hour group session at TOHPC in Ottawa on a scheduled weekday.

Exclusion Criteria:

  • Active mental health symptoms that significantly interfere with the ability to engage with psychoeducational content (e.g., dissociation, active psychosis), or participate in a group setting
  • Cognitive impairment that significantly limits the ability to comprehend study information, provide informed consent, or meaningfully engage with psychoeducational content.
  • Scheduled for a major surgical procedure within the study timeframe.
  • Currently receiving other individual or group psychotherapy that directly targets pain, pain cognitions, or pain-related emotional responses within the 12 weeks prior to enrollment.
  • Currently receiving interventional pain management services (e.g., injections, nerve blocks) from another clinic or institution within the 12-week period prior to enrollment through the 3-month follow-up.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Pain Reprocessing Therapy (PRT) session

The intervention involves a single 4-hour PRT in-person group session (up to 20 patients per group) at The Ottawa Hospital Pain Clinic, delivered by a PRT certified clinician.

The intervention is a brief mindfulness exercise (mindfulness of breath, energy, emotions, thoughts, sensations), followed by 90 minutes of didactic content focused on pain science education and foundation of pain reprocessing therapy. This includes interactive discussions, self-reflection, and skills building. This is followed by a brief exercise called predictive coding where participants are invited to draw a picture representing their pain. The remainder of the session includes gentle movement, somatic tracking, and practices to increase positive affect induction- specifically leaning into positive or neutral sensations and establishing short-term safety behaviours.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical Effectiveness: Brief Pain Inventory (BPI) Pain Intensity and Pain Interference
Time Frame: Baseline, 1 week post-intervention, 1 month follow up.

Clinical effectiveness outcome measurement tools include Brief Pain Inventory (BPI): Participants will localize their pain through a drop down menu, in which they will select the applicable body part(s) where they experience pain. The BPI Pain Intensity and Pain Interference scales will then be administered. The pain intensity subscale includes 4 pain intensity ratings using an 11-point numerical rating scale (0-10) on current pain, average pain, worst pain during the last 7 days and least pain during the last 24 hours. The pain interference subscale includes 7 interference items that ask the patient to respond using an 11-point numerical rating scale (0-10). These items include the effect on general activity, mood, walking ability, normal work (including housework), relations with other people, sleep, and enjoyment of life.

Baseline, 1 week post-intervention, 1 month follow up.
Interview
Time Frame: Interviews will be conducted within 6 months of participating in the PRT session.

A random selection of participants will be interviewed regarding their PRT experience.

Interviews will be conducted within 6 months of participating in the PRT session.
Clinical Effectiveness: Pain Self-Efficacy Questionnaire (PSEQ-10)
Time Frame: Baseline, 1 week post-intervention, 1 month follow up.

Clinical effectiveness outcome measurement tools include Pain Self-Efficacy Questionnaire (PSEQ-10): The PSEQ-10 is a validated 10-item tool for assessing the patient's pain self-efficacy or belief in one's capability to perform activities even when undergoing pain. The 10 items ask the patient to rate their confidence in doing activities on a 7-point numerical rating scale (0-6), with higher scores indicating greater confidence.

Baseline, 1 week post-intervention, 1 month follow up.
Clinical Effectiveness: Patients' Global Impression of Change (PGI-C) Scale
Time Frame: 1 week post-intervention, 1 month follow up.

Clinical effectiveness outcome measurement tools include Patients' Global Impression of Change (PGI-C) Scale: The PGI-C is a validated single- item self-report measure used to assess a patient's perceived change in overall status following a treatment or intervention. Patients select one of 7 options to describe their experience, ranging from "very much worse" to "very much improved." The PGI-C is widely used in chronic pain research and has demonstrated sensitivity to clinically meaningful change across a range of pain populations.

1 week post-intervention, 1 month follow up.
Clinical Effectiveness: Positive and Negative Affect Scale (PANAS)
Time Frame: Day of Intervention, 1 week post-intervention, 1 month follow up.

Clinical effectiveness outcome measurement tools include Positive and Negative Affect Scale (PANAS) PANAS is a validated 20-item self-report measure assessing two distinct dimensions of mood: positive affect and negative affect. Participants rate the extent to which they have experienced each emotion using a 5-point Likert scale (1 = very slightly or not at all, 5 = extremely), with higher positive affect scores and lower negative affect scores reflecting better emotional well-being. The PANAS has demonstrated strong reliability and validity across clinical populations, including individuals with chronic pain.

Day of Intervention, 1 week post-intervention, 1 month follow up.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility of recruitment
Time Frame: Baseline

• Rates of participant eligibility and consenting will be tracked

o The single session PRT model will be considered feasible if we can recruit our target sample size of 40 participants over a 6-month period.

Baseline
Rate of participant accrual/completion
Time Frame: Baseline, Day 7, and Day 30

• Rates of participant accrual, screening, and 1-week and 1-month assessment completion will be tracked

o The evaluation procedures will be considered feasible if we retain more than 80% of participants at 1-month follow-up.

Baseline, Day 7, and Day 30

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Susan Ward, MSW, The Ottawa Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 16, 2026

Primary Completion (Estimated)

May 1, 2027

Study Completion (Estimated)

October 1, 2027

Study Registration Dates

First Submitted

October 14, 2026

First Submitted That Met QC Criteria

October 30, 2026

First Posted (Actual)

November 5, 2026

Study Record Updates

Last Update Posted (Actual)

November 5, 2026

Last Update Submitted That Met QC Criteria

October 30, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 7131-20260398-01H

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.